Last updated: 2026-11-13 05:28:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
enGene Therapeutics Inc. (ENGN) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $2.29, with a market capitalization of $111.92M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.40 to $12.25. This page covers its latest market performance, valuation, price trends and company information.
$111.92M | |
$1.93 | |
$2.34 | |
$1.83 | |
$1.80 | |
11.71M | |
823.46K | |
-- | |
$12.25 | |
$1.40 | |
-- | |
-- |
enGene Therapeutics Inc. (ENGN) last closed at $2.29 as of 2026-11-13 01:00:00, up 27.22% ($0.49) from the previous close of $1.80.
During the latest regular trading session, ENGN traded between $1.83 and $2.34, with a volume of 11.71M shares. The closing price was near the upper end and near the lower end of its 52-week range.
ENGN is up 0.54% as of the last close.
Over the past seven days, enGene Therapeutics Inc. (ENGN) moved from $1.62 to $2.29, representing a gain of 41.17% ($0.67).
The stock traded between $1.45 and $2.34 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 1.26 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 8.2%
ENGN is currently trading at $2.29, placing it 8.2% of the way from its 52-week low of $1.40 to its 52-week high of $12.25. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 82 |
| Exchange | NASDAQ |
| Company Website |
View the latest dividend and stock split events for enGene Therapeutics Inc.
Dividend | |
|---|---|
| Ex-Dividend Date | -- |
| Payment Date | -- |
| Dividend Per Share | -- |
Stock Split | |
|---|---|
| Split Date | -- |
| Split Ratio | -- |
Latest news related to enGene Therapeutics Inc. and ENGN stock.
Gainers Addex Therapeutics (NASDAQ:ADXN) stock moved upwards by 73.5% to $5.01 during Thursday's regular session. enGene Therapeutics (NASDAQ:ENGN) stock rose 29.37% to $2.33. The company's market cap stands
Analysts upgraded AMD, Reliance, enGene, Mid Penn Bancorp and Republic Services, raising price targets for RS and MPB.
Piper Sandler analyst Allison Bratzel upgrades enGene Therapeutics (NASDAQ:ENGN) from Neutral to Overweight and maintains the price target from $4 to $4.
Wells Fargo analyst Yanan Zhu upgrades enGene Therapeutics (NASDAQ:ENGN) from Equal-Weight to Overweight and raises the price target from $2 to $6.
Eligible investors can buy real shares of enGene Therapeutics Inc. (ENGN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
See US stocks with the highest market capitalization
Discover today's most actively traded US stocks
Browse today's leading gainers in the US stock market
Explore the cryptocurrencies with the highest market capitalization
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to ENGN, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between ENGN shares and USD.
ENGN Shares to USD
1.00 ENGN shares = 2.287 USD
Calculations are estimates based on the latest available price and are for reference only.
